SP
ACAD icon

Symmetry Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Symmetry Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,528
Closed -$296K – 632
2020
Q4 		$296K Buy
5,528
+147
+3% +$7.3K 0.02% 525
2020
Q3 		$222K Buy
+5,381
New +$232K 0.02% 552

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Symmetry Partners's ACAD Position: Q1 2021 in Review

Symmetry Partners sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 5,528 shares — an estimated $296K sold.

Symmetry Partners first reported a position in ACAD in Q3 2020 and held it in 2 quarters. The position peaked at $296K in Q4 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Symmetry Partners reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Symmetry Partners sold 5,528 Acadia Pharmaceuticals shares in Q1 2021, an estimated $296K.
  • Symmetry Partners first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Symmetry Partners's Acadia Pharmaceuticals position peaked at $296K in Q4 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Symmetry Partners's 13F filing for Q1 2021, filed 3 May 2021.